Sage (SAGE) SRSE Data is Positive for Ligand Pharma (LGND) - Roth
Tweet Send to a Friend
Roth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a price target of $121.50 after Sage Therapeutics (Nasdaq: SAGE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
